Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT
| Autor: | Seong-Jang Kim, Won-Ku Lee, Junhee Han, Byung Soo Kim, Kyoungjune Pak, Hyun-Chang Ko, Gun-Wook Kim, Hoon-Soo Kim, Moon-Bum Kim |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Body surface area
medicine.medical_specialty PET-CT education.field_of_study business.industry Population Dermatology medicine.disease Gastroenterology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Psoriasis Area and Severity Index 030220 oncology & carcinogenesis Internal medicine Psoriasis Ustekinumab Severity of illness medicine Metabolic syndrome business education medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 80:1322-1331 |
| ISSN: | 0190-9622 |
| DOI: | 10.1016/j.jaad.2018.03.011 |
| Popis: | Background Evidence suggests that psoriasis may be associated with metabolic syndrome and an increased risk of cardiovascular disease. Objective To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT). Methods Patients with psoriasis and healthy controls underwent baseline 18 F-FDG PET/CT imaging. Among the patients with psoriasis, moderate to severe psoriasis was treated with ustekinumab, and the patients underwent 18 F-FDG PET/CT again after a Psoriasis Area and Severity Index of 75 was achieved. Results After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and five parts of the aorta ( P Limitations Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population. Conclusion Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect